Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2015.01.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review.
J Acad Consult Liaison Psychiatry
January 2025
Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA, 33613; Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, 32608.
Background: Neuroleptic malignant syndrome (NMS) is a rare yet potentially fatal iatrogenic syndrome that can manifest with life-threatening symptoms. Theorized to be caused by the dopamine-blocking effects of certain medications, such as antipsychotics, or the withdrawal of dopaminergic agents, NMS is characterized by hyperthermia, autonomic instability, altered mental status, and muscular rigidity. Most treated cases resolve within weeks; however, in some cases, residual catatonic symptoms can persist for months after the resolution of acute hyperthermic and hypermetabolic symptoms.
View Article and Find Full Text PDFFavorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child.
Int Immunopharmacol
January 2025
Department of Pediatrics, the First Medical Centre, Chinese PLA General Hospital, Beijing, China; Senior Department of Pediatrics, the Seventh Medical Center of PLA General Hospital, Beijing, China; Medical School of Chinese People's Liberation Army, Beijing, China. Electronic address:
Febrile Infection-Related Epilepsy Syndrome (FIRES) is an infrequent yet severe form of epilepsy that rapidly evolves into status epilepticus following a febrile episode. Prompt diagnosis coupled with effective treatment strategies is critical for improving patient outcomes. Herein, we describe the case of an 11-year-old male with FIRES who was successfully treated with tocilizumab, resulting in no further seizures or residual disability.
View Article and Find Full Text PDFPET/CT: Clinical role in lymphomas.
Hell J Nucl Med
November 2023
Nuclear Medicine Department, University Hospital of Larissa, Greece.
F-FDG PET/CT is the imaging modality of choice for the accurate initial staging of most lymphomas. Hodgkin's, Diffuse Large B-cell and follicular lymphomas show avid FDG uptake, while a minority of Non-Hodgkin lymphoma subtypes namely MALT, marginal and small lymphocytic lymphoma demonstrate low or moderate avidity. As a rule of thumb, indolent lymphomas show lower FDG activity than aggressive ones.
View Article and Find Full Text PDFCirculating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.
Blood Adv
August 2023
Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer and Research Institute, Tampa, FL.
We examined the meaning of metabolically active lesions on 1-month restaging nuclear imaging of patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel (axi-cel) by assessing the relationship between total metabolic tumor volume (MTV) on positron emission tomography (PET) scans and circulating tumor DNA (ctDNA) in the plasma. In this prospective multicenter sample collection study, MTV was retrospectively calculated via commercial software at baseline, 1, and 3 months after chimeric antigen receptor (CAR) T-cell therapy; ctDNA was available before and after axi-cel administration. Spearman correlation coefficient (rs) was used to study the relationship between the variables, and a mathematical model was constructed to describe tumor dynamics 1 month after CAR T-cell therapy.
View Article and Find Full Text PDFAccuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
Urol Int
March 2023
ReSurg SA, Nyon, Switzerland.
Article Synopsis
- - The study aimed to assess the accuracy of a second FDG-PET/CT scan in evaluating patients with localized muscle-invasive bladder cancer after receiving neoadjuvant chemotherapy before radical cystectomy.
- - A total of 62 patients were reviewed, and after exclusions, 45 patients were analyzed, with FDG-PET/CT showing a sensitivity of over 95% but lower specificity in identifying complete responders and residual disease compared to histopathology.
- - The findings indicate that FDG-PET/CT can effectively identify patients who may need alternative treatment avenues if they do not respond completely to chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!